

Exhibit C

From: [Van Horn, Shaun M.](#)
To: [Fletcher, Thomas](#); [Tuchman, Haley B.](#)
Cc: [Fogel, Louis E.](#); [DL_FYB203Internal](#); [Eylea](#); [Eylea Biosimilars](#)
Subject: RE: FYB 203: Regeneron's (I)(3)(A) List
Date: Friday, November 10, 2023 12:41:31 PM

Tom,

Thanks for the proposal below. We have discussed it with Formycon and are hoping you might have time this afternoon or Monday to discuss how this would work in a bit more detail, e.g., which court we'd file in, how it would relate to any parallel biosimilar proceedings, how we'd deal with the court's schedule/input, and what we'd do about the remainder of the case schedule. Let us know what works for you.

Best,
Shaun

From: Fletcher, Thomas <TFletcher@wc.com>
Sent: Thursday, November 9, 2023 8:49 AM
To: Tuchman, Haley B. <HTuchman@jenner.com>
Cc: Fogel, Louis E. <LFogel@jenner.com>; Van Horn, Shaun M. <SVanHorn@jenner.com>; DL_FYB203Internal <DL_FYB203Internal@jenner.com>; Eylea <Eylea@wc.com>; Eylea Biosimilars <Eylea.Biosimilars@weil.com>
Subject: RE: FYB 203: Regeneron's (I)(3)(A) List

External Email - Do Not Click Links or Attachments Unless You Know They Are Safe

Counsel,

With the end of regulatory exclusivity approximately 6 months away, please let us know if Formycon would be willing to proceed on the below schedule for preliminary injunction proceedings once an infringement action has been filed.

Note that we have included a date to suggest to the Court when a ruling is necessary based on our estimate of when FDA might approve your BLA—if you believe that date is inaccurate, please let us know. In any event, to give the Court the opportunity to evaluate the parties' position, this proposal assumes that you will promise to the Court that you will not commercialize your aflibercept biosimilar product prior to the Court's decision on the preliminary injunction motion.

Best,

Tom

Date

Event

November 16, 2023

Regeneron to identify list of no more than 4 patents to include in motion for preliminary injunction

November 22, 2023

Parties exchange targeted requests for production

December 22, 2023

Formycon to identify no more than 3 invalidity arguments per patent for purpose of the PI hearing only—for clarity, each prior art combination or anticipatory reference is one argument

January 19, 2024

Document production complete

February 23, 2024

Regeneron to file motion for preliminary injunction

March 8, 2024

Depositions of Regeneron declarants complete

March 22, 2024

Formycon to file opposition

April 5, 2024

Deposition of Formycon declarants complete

April 19, 2024

Regeneron Reply ISO preliminary injunction

Week of May 13, 2024

Proposed hearing

June 25, 2024

Estimated date of decision on preliminary injunction

Thomas S. Fletcher
Williams & Connolly LLP
680 Maine Ave. SW
Washington, DC 20024
(202) 434-5497

From: Fletcher, Thomas <TFletcher@wc.com<<mailto:TFletcher@wc.com>>>
Sent: Tuesday, November 7, 2023 4:40 PM
To: 'Tuchman, Haley B.' <HTuchman@jenner.com<<mailto:HTuchman@jenner.com>>>
Cc: Fogel, Louis E. <LFogel@jenner.com<<mailto:LFogel@jenner.com>>>; Van Horn, Shaun M.
<SVanHorn@jenner.com<<mailto:SVanHorn@jenner.com>>>; DL_FYB203Internal
<DL_FYB203Internal@jenner.com<mailto:DL_FYB203Internal@jenner.com>>; Eylea
<Eylea@wc.com<<mailto:Eylea@wc.com>>>; Eylea Biosimilars
<Eylea.Biosimilars@weil.com<<mailto:Eylea.Biosimilars@weil.com>>>
Subject: FYB 203: Regeneron's (l)(3)(A) List

Counsel,

Please see the attached letter with Regeneron's list of patents pursuant to 42 U.S.C. § 262(l)(3)(A), and if you have any trouble with the attached, please let me know.

Regards,

Tom

Thomas S. Fletcher
Williams & Connolly LLP
680 Maine Ave. SW
Washington, DC 20024
(202) 434-5497

From: Tuchman, Haley B. <HTuchman@jenner.com<<mailto:HTuchman@jenner.com>>>
Sent: Friday, September 8, 2023 12:37 PM
To: Fletcher, Thomas <TFletcher@wc.com<<mailto:TFletcher@wc.com>>>
Cc: Fogel, Louis E. <LFogel@jenner.com<<mailto:LFogel@jenner.com>>>; Van Horn, Shaun M.
<SVanHorn@jenner.com<<mailto:SVanHorn@jenner.com>>>
Subject: FYB 203 Production

Tom,

Please see the attached correspondence regarding Formycon AG's production of BLA No. 761378.

Regards,

Haley

Haley B. Tuchman

Jenner & Block LLP
1099 New York Avenue, NW
Suite 900, Washington, DC 20001-4412 | jenner.com<<http://www.jenner.com>>
+1 202 639 5351 | TEL
+1 771 215 0622 | MOBILE
Pronouns: She / Her
HTuchman@jenner.com<<mailto:HTuchman@jenner.com>>
Download V-Card<<https://svcs.jenner.com/JBvCard/vcardhandler/getcardbyid/76453>> | View
Biography<<http://www.jenner.com/people/HaleyTuchman>>

CONFIDENTIALITY WARNING: This email may contain privileged or confidential information and is for the sole use of the intended recipient(s). Any unauthorized use or disclosure of this communication is prohibited. If you believe that you have received this email in error, please notify the sender immediately and delete it from your system.

This message and any attachments are intended only for the addressee and may contain information that is privileged and confidential. If you have received this message in error, please do not read, use, copy, distribute, or disclose the contents of the message and any attachments. Instead, please delete the message and any attachments and notify the sender immediately. Thank you.